Yazar "Yurdaydin, C." seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe 72 week data of the HIDIT-1 trial(Elsevier Science Bv, 2007) Wedemeyer, H.; Yurdaydin, C.; Dalekos, G.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.[Abstract Not Available]Öğe ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA(Elsevier Science Bv, 2013) Wranke, A.; Yurdaydin, C.; Heidrich, B.; Caruntu, F. A.; Curescu, M. G.; Yalcin, K.; Gurel, S.[Abstract Not Available]Öğe Anti-HDV-IgM as a marker of disease activity in hepatitis delta(Springer, 2013) Wranke, A.; Yurdaydin, C.; Heidrich, B.; Caruntu, F.; Curescu, M.; Yalcin, K.; Gurel, S.[Abstract Not Available]Öğe ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT(Elsevier Science Bv, 2010) Mederacke, I.; Yurdaydin, C.; Bremer, B.; Cakaloglu, Y.; Erhardt, A.; Yalcin, K.; Zachou, K.[Abstract Not Available]Öğe LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA(Elsevier Science Bv, 2013) Heidrich, B.; Yurdaydin, C.; Kabacam, G.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.[Abstract Not Available]Öğe A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis(Blackwell Publishing, 2007) Yurdaydin, C.; Bozkaya, H.; Karaaslan, H.; Oender, F. O.; Erkan, Oe. E.; Yalcin, K.; Degertekin, H.High dose interferon treatment for 1 year is the only established treatment for chronic hepatitis D, but it is associated with a high relapse rate after treatment discontinuation. In this study, patients were treated with 10 MU interferon alpha 2b, thrice weekly for 2 years. Twenty-three patients were recruited and 15 completed the 2-year treatment and 6 months follow-up periods. Treatment response was assessed biochemically [normal alanine aminotransferase (ALT)], virologically (undetectable hepatitis D virus RNA) and histologically (at least 2 point decrease in the Knodell score) at the end of treatment (EOT) and at the end of follow-up. Out of 15 patients who finished the 2-year treatment period, seven patients (47%) had a biochemical response but only two (13%) had a normal ALT after follow-up. ALT decreased from the baseline value of 143.1 +/- 121.7 (mean +/- SD) to 39.7 +/- 20.6 (P < 0.01) at EOT. Virological response was observed in six patients at EOT and in two patients at follow-up. Two patients lost hepatitis B surface antigen. Of the 12 patients with paired liver biopsies, a histological improvement was observed in eight patients. Interferon treatment leads to a complete or partial response in a substantial number of patients but 2 years of treatment does not appear to increase sustained response rates over 1 year treatment.Öğe PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-?-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY(Elsevier Science Bv, 2014) Wedemeyer, H.; Yurdaydin, C.; Ernst, S.; Caruntu, F. A.; Curescu, M. G.; Yalcin, K.; Akarca, U. S.[Abstract Not Available]Öğe Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection(Wiley, 2012) Mederacke, I.; Yurdaydin, C.; Grosshennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.. Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNa). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNa-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNa-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by CockcroftGault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNa-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR =20% was observed more often in patients during adefovir-containing treatment vs PegIFNa-2a alone (P < 0.05) which was confirmed by KaplanMeier analysis. Adefovir-containing but not PegIFNa-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNa-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function.Öğe Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the HEP-NET/International HDV Intervention Trial(Elsevier Science Bv, 2006) Zachou, K.; Yurdaydin, C.; Dienes, H. R.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.[Abstract Not Available]Öğe Treatment of chronic delta hepatitis with lamivudine vs lamivudine plus interferon vs interferon(Wiley, 2008) Yurdaydin, C.; Bozkaya, H.; Onder, F. O.; Senturk, H.; Karaaslan, H.; Akdogan, M.; Cetinkaya, H.Chronic delta hepatitis is the most severe form of chronic viral hepatitis for which interferon (IFN) is the only available treatment. In 39 patients (25 were treatment-naive, 14 had previously used IFN), efficacy of 1-year treatment with IFN (9 MU, t.i.w.) or lamivudine (LAM; 100 mg, q.d.) alone was compared with IFN and LAM combination (2 months of LAM to be followed by combination treatment). IFN monotherapy was given only to treatment-naive patients. In both treatment-naive and previous IFN users, end of treatment virological and biochemical responses were similar with IFN-LAM combination and superior to LAM monotherapy (P < 0.05). Improvement in liver histology occurred more often with IFN +/- LAM than with LAM alone (P < 0.05). In treatment-naive patients, combination treatment was not superior to IFN monotherapy. After treatment discontinuation, virological and biochemical response rates decreased in LAM and IFN combination and IFN monotherapy. On treatment virological response at month 6 of treatment predicted sustained virological response. The results of this study suggest that addition of LAM to IFN for the treatment of delta hepatitis is of no additional value and that both treatment modalities are superior to LAM monotherapy.Öğe A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study(Elsevier Science Bv, 2018) Wranke, A.; Yurdaydin, C.; Heidrich, B.; Kalliopi, Z.; Yalcin, K.; Fehmi, T.; Akarca, U.[Abstract Not Available]
